# A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

> **NCT02799381** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 63 (actual)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **DRUG:** Optimized antiparkinsonian treatment
- **DRUG:** Levodopa-Carbidopa Intestinal Gel (LCIG)
- **DEVICE:** CADD-Legacy ambulatory infusion pump
- **DEVICE:** Percutaneous endoscopic gastrostomy tube
- **DEVICE:** Jejunal extension tube

## Key facts

- **NCT ID:** NCT02799381
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-09
- **Primary completion:** 2019-09-19
- **Final completion:** 2019-09-19
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2020-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02799381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02799381, "A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02799381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*